Skip to main content
Equibles
HQY logo

HQY · Healthequity, Inc. · Metrics

Track HQY — free

Use HQY with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research HQY.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$96.26 +1.71 (+1.81%) At close · Sep 11
S&P 400 member Russell 2000 member Rebalance outlook locked
Market Cap
$7.96B
Shares
82.72M

HQY metrics

93 of 115 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$96.26
Market cap
$7.96B

Price action

20 metrics
Price change (1W)
+0.2%
Price change (30D)
-8.1%
Price change (3M)
+9.0%
Price change (6M)
+23.7%
Price change (YTD)
+5.1%
Price change (1Y)
+4.2%
Trailing year
Price change (5Y)
+50.9%
52-week high
$106.79
52-week low
$73.21
Change from 52-week high
-9.9%
Change from 52-week low
+31.5%
Annualized volatility
35.5%
Annualized volatility (3M)
36.7%
Beta
0.6
RSI (14D)
44.6
Price vs SMA 50
-3.3%
Price vs SMA 200
+7.9%
Avg volume (3M)
866,867
Relative volume
0.8
Average dollar volume
$82.86M

Company

3 metrics
Sector
Healthcare
Industry
Health Information Services
Shares outstanding
82.72M

Valuation

12 metrics
P / E (TTM)
34.8
Trailing earnings · reciprocal yield 2.9%
PEG ratio
2.4
EV / revenue
6.3×
reciprocal yield 15.8%
EV / EBITDA
17.0×
reciprocal yield 5.9%
EV / EBIT
24.6×
reciprocal yield 4.1%
P / sales
5.8×
reciprocal yield 17.1%
P / book
4.0
reciprocal yield 25.0%
FCF yield
6.1%
TTM · current market cap
Buyback yield
5.1%
P / FCF
16.3
reciprocal yield 6.1%
P / operating cash flow
16.2
reciprocal yield 6.2%
Earnings yield
3.0%

Historical valuation

8 metrics
P / E historical average (3Y)
106.7×
reciprocal yield 0.9%
P / E historical average (5Y)
570.3×
reciprocal yield 0.2%
EV / revenue historical average (3Y)
7.0×
reciprocal yield 14.3%
EV / revenue historical average (5Y)
7.0×
reciprocal yield 14.2%
EV / EBIT historical average (3Y)
48.7×
reciprocal yield 2.1%
EV / EBIT historical average (5Y)
242.9×
reciprocal yield 0.4%
EV / EBITDA historical average (3Y)
23.5×
reciprocal yield 4.3%
EV / EBITDA historical average (5Y)
31.0×
reciprocal yield 3.2%

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
5.1%
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
—
Last earnings
2026-08-27

Profitability

9 metrics
Gross margin
71.2%
Operating margin
25.8%
Trailing 12 months
Net margin
17.4%
Gross profit (TTM)
$970.48M
Operating profit (TTM)
$351.41M
Net income (TTM)
$236.49M
Trailing 12 months
Diluted EPS (TTM)
$2.77
FCF margin
35.8%
Effective tax rate
23.4%

Per share

11 metrics
Revenue per diluted share (TTM)
—
Gross profit per diluted share (TTM)
—
Operating profit per diluted share (TTM)
—
EBITDA per diluted share (TTM)
—
Net income per diluted share (TTM)
—
Operating cash flow per diluted share (TTM)
—
Free cash flow per diluted share (TTM)
—
Capital expenditures per diluted share (TTM)
—
R&D per diluted share (TTM)
—
Stock compensation per diluted share (TTM)
—
Book value per share
$24.79

Growth

11 metrics
Revenue growth YoY
+7.6%
Year over year
Net income growth YoY
+9.7%
Revenue (TTM)
$1.36B
Trailing 12 months
EPS growth YoY
+14.7%
Shares change YoY
-4.3%
Year over year · fewer shares
Revenue CAGR (3Y)
+15.1%
Revenue CAGR (5Y)
+12.4%
EPS CAGR (3Y)
—
EPS CAGR (5Y)
+83.0%
FCF CAGR (3Y)
+45.7%
FCF CAGR (5Y)
+22.0%

Quality

14 metrics
Return on equity
11.9%
Return on assets
7.2%
Debt / equity
0.5
Current ratio
3.0
EBITDA (TTM)
$509.04M
Free cash flow (TTM)
$487.73M
Quick ratio
—
Interest coverage
6.7
Net debt / EBITDA
1.3
Return on invested capital
10.1%
Trailing 12 months
Net cash
−$675.06M
Latest balance sheet
Cash & equivalents
$256.00M
Total assets
$3.27B
Total debt
$931.06M

Cash flow & spend

7 metrics
Operating cash flow (TTM)
$490.18M
Capital expenditures (TTM)
$2.45M
R&D (TTM)
$277.96M
SG&A (TTM)
—
Stock compensation (TTM)
$81.28M
R&D / revenue
20.4%
Stock compensation / revenue
6.0%

Ownership (13F)

3 metrics
13F filers
499
13F filer change QoQ
+10
Institutional ownership
108.2%

Short interest

3 metrics
Short interest
5.5%
Latest settlement · 4.3 days to cover
Days to cover
4.3d
Short-squeeze score
67 / 100

Insider activity

2 metrics
Net insider buying (90D)
−$1.26M
Insider-sentiment score
—

Risk flags

1 metrics
Going concern
—
Key facts CIK 1428336 CUSIP 42226A107 13F (30d) 121 filings 119 filers Visit website Investor relations